ACC
This channel contains news about the American College of Cardiology (ACC), including coverage of its annual meeting and links to recently released practice guidelines. The ACC is a leading resource for cardiology professionals, including all its subspecialties.
Videos | Structural Heart | April 01, 2020
A review of the PARTNER 3 Low-Risk Trial with Michael Mack, M.D., chairman, cardiovascular service line, Baylor Scott...
News | March 30, 2020
March 30, 2020 — Smokers who received smoking cessation counseling and used electronic cigarettes (e-cigarettes)...
Closing access to the radial artery after harvesting a section of the artery for a coronary artery bypass graft (CABG). Photo by Getty Images.
News | Cardiovascular Surgery | March 30, 2020
March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when...
Sponsored Content
An example of the new generation of inexpensive, wearable cardiac monitors that are seeing increased usage. This is the Cardiac Insight Cardea Solo device. After the monitoring period is over, the wearable patch is torn open to retrieve a data pod that is inserted into a reader to download the data. The software automatically creates reports based on the data, complete with waveforms for various cardiac measures.
Blog | Cardiac Diagnostics | May 10, 2018
The show floors at the American College of Cardiology (ACC) 2018 meeting in March and at the Heart Rhythm Society (...
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — A group of 13 U.S. medical societies sent an open letter to Congress appealing to them to do what is...
Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20.
News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) did...
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well...
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing...
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational...
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve...
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing...
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.
News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran...
Women carry heavier burden of chest pain, but less artery narrowing, according to data in a substudy from the ISCHEMIA Trial.
News | Womens Cardiovascular Health | March 28, 2020
March 28, 2020 — Women with coronary artery disease that reduces blood flow and oxygen to the heart muscle (ischemia)...
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of...
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting.
News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to...
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with...
